JP2022538286A5 - - Google Patents

Info

Publication number
JP2022538286A5
JP2022538286A5 JP2021577316A JP2021577316A JP2022538286A5 JP 2022538286 A5 JP2022538286 A5 JP 2022538286A5 JP 2021577316 A JP2021577316 A JP 2021577316A JP 2021577316 A JP2021577316 A JP 2021577316A JP 2022538286 A5 JP2022538286 A5 JP 2022538286A5
Authority
JP
Japan
Prior art keywords
therapeutic composition
composition according
compound
acid
lmtx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021577316A
Other languages
English (en)
Japanese (ja)
Other versions
JP7610537B2 (ja
JP2022538286A (ja
Filing date
Publication date
Priority claimed from GBGB1909506.6A external-priority patent/GB201909506D0/en
Application filed filed Critical
Publication of JP2022538286A publication Critical patent/JP2022538286A/ja
Publication of JP2022538286A5 publication Critical patent/JP2022538286A5/ja
Application granted granted Critical
Publication of JP7610537B2 publication Critical patent/JP7610537B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021577316A 2019-07-02 2020-06-29 シナプス変性症の処置における使用のためのメチルチオニニウム Active JP7610537B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1909506.6 2019-07-02
GBGB1909506.6A GB201909506D0 (en) 2019-07-02 2019-07-02 Synaptopathies
PCT/EP2020/068306 WO2021001326A1 (en) 2019-07-02 2020-06-29 Methylthioninium for use in the treatment of synaptopathies

Publications (3)

Publication Number Publication Date
JP2022538286A JP2022538286A (ja) 2022-09-01
JP2022538286A5 true JP2022538286A5 (enExample) 2023-07-07
JP7610537B2 JP7610537B2 (ja) 2025-01-08

Family

ID=67540130

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021577316A Active JP7610537B2 (ja) 2019-07-02 2020-06-29 シナプス変性症の処置における使用のためのメチルチオニニウム

Country Status (12)

Country Link
US (1) US20220370470A1 (enExample)
EP (1) EP3993805A1 (enExample)
JP (1) JP7610537B2 (enExample)
KR (1) KR20220029711A (enExample)
CN (1) CN114080224A (enExample)
AU (1) AU2020300792B2 (enExample)
BR (1) BR112021025383A2 (enExample)
CA (1) CA3143787A1 (enExample)
GB (1) GB201909506D0 (enExample)
IL (1) IL289371A (enExample)
MX (1) MX2021015288A (enExample)
WO (1) WO2021001326A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY148145A (en) 2006-07-11 2013-03-15 Wista Lab Ltd Methods of synthesis and/or purification of diaminophenothiazinium compounds
FI4385512T3 (fi) 2018-07-26 2026-01-12 Taurx Therapeutics Man Ltd Diaminofenotiatsiinien optimoitu annostus populaatioille
WO2021211640A1 (en) * 2020-04-14 2021-10-21 University Of Florida Research Foundation, Incorporated Enhanced effects of gene-immunotherapy and immunosuppressants in multiple sclerosis
US12410394B2 (en) 2023-01-06 2025-09-09 Athergen, Inc. Composition comprising nicotinamide mononucleotide and leucomethylene blue

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020040032A1 (en) 2000-07-07 2002-04-04 Glasky Michelle S. Methods for stimulation of synthesis of synaptophysin in the central nervous system
GB0100119D0 (en) 2001-01-03 2001-02-14 Univ Aberdeen Materials and methods relating to protein aggregation in neurodegenerative disease
ES2349322T7 (es) 2006-03-29 2019-10-17 Wista Lab Ltd Sales de 3,7-diamino-10H-fenotiazina y su utilización
AU2008265045B2 (en) 2007-06-19 2014-02-27 Taurx Therapeutics Management Ltd. Phenothiazine compounds for treating Mild Cognitive Impairment
CA2701075C (en) 2007-10-03 2019-02-12 Wista Laboratories Ltd. Therapeutic use of diaminophenothiazines.
JP5898701B2 (ja) 2011-02-11 2016-04-13 ウィスタ ラボラトリーズ リミテッド フェノチアジンジアミニウム塩およびそれらの使用
JP7073330B2 (ja) * 2016-07-25 2022-05-23 ウィスタ ラボラトリーズ リミテッド ジアミノフェノチアジンの投与及び投与量
GB201614834D0 (en) 2016-09-01 2016-10-19 Wista Lab Ltd Treatment of dementia
JP6756661B2 (ja) 2017-04-28 2020-09-16 日立オートモティブシステムズ株式会社 車両電子制御装置

Similar Documents

Publication Publication Date Title
JP2022538286A5 (enExample)
EP2323696B1 (en) Optical method for the detection of alzheimer's disease
JP2015510941A5 (enExample)
JP2018035197A5 (enExample)
JP2024516371A5 (enExample)
JP2022515293A5 (enExample)
JP2019532029A5 (enExample)
JP2009510044A5 (enExample)
Prasetyo The primary, secondary, and tertiary brain injury
JP2015508092A5 (enExample)
JP2019529541A5 (enExample)
JP2018534286A5 (enExample)
JP2020504156A5 (enExample)
JP2009501202A5 (enExample)
JP2019529514A5 (enExample)
JP2013544786A5 (enExample)
JP2019515040A5 (enExample)
JP2024531437A5 (enExample)
JP2018509426A5 (enExample)
US20160193143A1 (en) Medicinal treatment of dermal infectious disorders with norketotifen
JP2022524111A5 (enExample)
JP2022552520A5 (enExample)
JP2009526834A5 (enExample)
CA2886194C (en) Medicinal treatment of chronic dermal inflammatory diseases with norketotifen
JP2022512373A5 (enExample)